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Triple begative breast cancer (TNBC) accounts 
approximately for 15 percent of breast cancers di-
agnosed worldwide, which accounts for almost 
200,000 cases each year [1]. In Portugal, in 2018, 
the number of new diagnosed cases of breast cancer 
was 6,974 [2]. TNBC is defined as: ≤ 1% expression 
of estrogen receptor (ER) and progesterone recep-
tor (PR) by immunohistochemistry (IHC), and hu-
man epidermal growth factor receptor 2 (HER2) 
that are either 0 to 1+ by IHC, or IHC 2+ and 
fluorescence in situ hybridization (FISH)-negative 
(not amplified), according to the American Society 
of Clinical Oncology/College of American Patholo-
gists (ASCO/CAP) guidelines [3, 4].
AbstrAct
background: Triple negative breast cancer (TNBc) has the worst prognosis amongst all subtypes. studies have shown that the 
achievement of pathologic complete response in the breast and axilla correlates with improved survival. The aim of this study 
was to identify clinical or pathological features of real-life TNBc patients with a higher risk of early relapse.
Materials and methods: single-centre retrospective analysis of 127 women with TNBc, stage II–III, submitted to neoadjuvant 
treatment and surgery between January 2016 and 2020. Multivariate cox regression analysis for disease free survival (DFs) at 
2 years was performed and statistically significant variables were computed into a prognostic model for early relapse.
results: after 29 months of median follow-up, 105 patients (82.7%) were alive and, in total, 38 patients (29.9%) experienced 
recurrence. The 2-year DFs was 73% (95% cI: 21.3–22.7). In multivariate analysis, being submitted to neoadjuvant radiotherapy 
[hr 2.8 (95% cI: 1.2–6.4), p = 0.017] and not achieving pathologic complete response [hr 0.3 (95% cI: 0.1–1.7), p = 0.011] were 
associated with higher risk of recurrence. In our prognostic model, the presence of at least one of these variables defined 
a subgroup of patients with a worse 2-year DFs than those without these features (59% vs. 90%, p < 0.001, respectively).  
conclusions: In this real-life non-metastatic TNBc cohort, neoadjuvant radiotherapy (performed due to insufficient clinical 
response to neoadjuvant chemotherapy or significant toxicity) impacted as an independent prognostic factor for relapse 
along with the absence of pathologic complete response identifying a subgroup of higher risk patients for early relapse that 
might merit a closer follow-up.
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The majority of TNBCs are histologically de-
fined as non-specific invasive breast cancer (ap-
proximately 95%) and the other 5% are infiltrating 
lobular carcinoma, secretory cancer, medullary car-
cinoma, adenoid cystic carcinoma and fibromato-
sis–like spindle-cell metaplastic carcinoma [5]. This 
small proportion of TNBCs have a low aggressive 
potential and follow an indolent course contrasting 
with the invasive ductal carcinomas which are as-
sociated with high rates of early distant recurrence 
and short survival times compared to other breast 
cancer subtypes [6–12]. 
Unlike other breast cancer subtypes, there are no 
approved targeted treatments available, although 
immunotherapy (in combination with chemother-
apy) is available for those with advanced TNBC that 
expresses programmed cell death ligand 1. There-
fore, chemotherapy is still the standard of care for 
early and late stages of TNBC patients. Many stud-
ies have demonstrated the benefit of chemotherapy 
in neoadjuvant, adjuvant and metastatic setting 
in TNBC. Neoadjuvant chemotherapy (NACT) is 
the preferred treatment approach to potentially 
increase the likelihood of tumor resectability and 
breast conservation. TNBC tends to behave more 
aggressively being associated with the worst prog-
nosis amongst all breast cancer subtypes. The risk of 
distant recurrence and death peaks at approximate-
ly three years after diagnosis and declines rapidly 
thereafter [13]. During this period, TNBC is char-
acterized by higher relapse rates compared with 
hormone receptor positive breast cancers, although 
the latter tends to continue to recur for decades. 
Patients with TNBC have a poorer short-term (first 
five to seven years) prognosis compared with pa-
tients with other breast cancer subtypes [3, 6].
A subgroup of TNBCs is inherently chemo-
sensitive and achieves a pathological complete 
response (pCR) following combination anthracy-
cline/taxane-based NACT [8–14]. These patients 
who achieve pCR after NACT have a higher rate of 
survival compared to those with residual disease [6, 
14]. The basis for this variation in response to che-
motherapy and survival remains unclear. In gen-
eral, in breast cancer, tumor size is correlated with 
nodal involvement, and the prognostic value of the 
two factors is independent of each other. Never-
theless, in TNBC, the correlation between tumor 
size and lymph node status may not be linear since 
even the small tumors may have a high rate of node 
positivity [15]. In fact, in TNBC, the nodal status 
has been described as an independent prognostic 
factor [16].
The aim of our retrospective study is to analyse 
the clinicopathological characteristics and prognos-
tic significance of putative prognostic factors in 
TNBC as well as to determine short-term outcomes 
in these patients at our institution.
Materials and methods
study design and data source
This is single-centre retrospective analysis of 
127 women with non-metastatic TNBC. Data re-
garding patient characteristics, tumor pathological 
characteristics, analytical workup, treatment data, 
toxicities and outcomes were reviewed and ana-
lyzed retrospectively from the patient’s electronic 
medical records from the Portuguese Oncology In-
stitute of Coimbra Francisco Gentil. The study was 
reviewed and approved by the Ethics Committee 
of the Portuguese Oncology Institute of Coimbra 
Francisco Gentil and a waiver of written informed 
consent from patients was granted considering the 
retrospective nature of the study.
patients eligibility
Eligible patients were ≥ 18 years old, diagnosed 
with non-metastatic TNBC treated between Janu-
ary 2016 and January 2020. All patients underwent 
NACT and/or NART and surgery (breast conserv-
ing surgery or modified radical mastectomy). Pa-
tients with metastatic presentation, patients with-
out histologically documentation of TNBC, pa-
tients who underwent upfront breast surgery and 
patients not eligible for neoadjuvant treatment were 
excluded.
Definitions
Breast tumors with IHC-negative ER and PR as-
sociated with HER-2 score 0 or 1 with IHC staining 
or FISH negative expression were defined as TNBC. 
Tumors were staged according to guidelines [17]. 
A pCR was defined as no residual invasive disease 
in the breast, with or without residual in situ dis-
ease, and no residual disease in the axillary lymph 
nodes (ypT0/is ypN0). Disease free survival (DFS) 
was defined as the time from the beginning of neo-
adjuvant treatment until disease recurrence detec-
tion. Overall survival (OS) was defined as the time 
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from diagnosis to death or last follow-up. Toxicities 
were graded according to CTCAE version 5.
statistical analysis
Chi-square tests and analysis of variance (ANO-
VA) or Kruskal-Wallis tests were used to assess 
differences in categorical and continuous variables. 
Categorical variables were described in percent-
ages. Continuous variables were characterized by 
median and specific interval. For some continuous 
variables, like tumor markers CEA and CA 15.3, 
neutrophil/lymphocyte ratio, platelet/lymphocyte 
ratio and Ki-67, the cut-off used for the Cox regres-
sion analysis was determined by ROC curve and 
determination of the Youden Index. CEA and CA 
15.3 ratios were calculated by dividing the value be-
fore the beginning of neoadjuvant treatment by the 
value after surgery. Neutrophil/lymphocyte ratio 
was calculated by dividing the number of neutro-
phils by the number of lymphocytes from the com-
plete blood count before the start of neoadjuvant 
treatment, and platelet/lymphocyte ratio was cal-
culated by dividing the number of platelets by the 
number of lymphocytes from the complete blood 
count before the start of neoadjuvant treatment.
A univariate logistic regression analysis was used 
to estimate the associations between demographic, 
clinicopathologic, tumor and treatment character-
istics with survival outcomes (DFS and OS at 24 
months). The characteristics were selected based 
on statistical significance which was set at p < 0.05. 
All the characteristics considered significant in the 
univariate analysis were included in the multivari-
ate Cox regression analysis. We report hazard ra-
tios (HR) and 95% confidence intervals (CI) with 
p < 0.05 considered significant. Based on the results 
of the multivariate analysis for DFS, a risk model 
was created. Survival plots were generated with the 
Kaplan-Meier method with log-rank p < 0.05 de-
fined as significant. All analyses were conducted us-
ing the Statistical Package for Social Sciences (SPSS 
v26.0, SPSS Inc., Chicago, IL, USA) software.
results
patient characteristics
From January 2016 through January 2020, 127 
patients were analyzed. The baseline demographic, 
disease and tumor characteristics are represented 
in Table 1. Briefly, the median age was 52 years [in-
table 1. patient and tumor characteristics
No. (%)
age (y), median [range] 52 [26–74]












Ductal invasive carcinoma 110 (86.6)
apocrine carcinoma 8 (6.3)








≥ 70% 73 (57.5)

















≥ 1.8 74 (58.3)
< 1.8 53 (41.7)
Platelet/lymphocyte ratio
≥ 0.1 × 103 59 (46.5)
< 0.1 × 103 68 (53.5)
ecOG ps — eastern cooperative Oncology Group performance status;  
y — years; no. — number
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terval 26–74 years], the majority of patients had an 
Eastern Cooperative Oncology Group performance 
status (ECOG PS) of 0, 34% were premenopausal 
and only 5% were BRCA mutated. Concerning the 
histologic subtype, the majority of patients had duc-
tal invasive carcinoma, 93% had Modified Bloom 
Richardson (MBR) pathologic grade 2 or 3 and 
58% had Ki67 ≥ 70%. The majority of patients had 
a clinical T status ≥ 3, clinical N status ≥ 1 and 73% 
had stage III disease according to the 8th edition of 
the American Joint Committee on Cancer (AJCC) 
classification. The pre-treatment neutrophil/lym-
phocyte ratio was ≥ 1.80 in 58% of patients and the 
platelet/lymphocyte ratio was ≥ 0.1 x 103 in 47%.
Treatment, toxicities and response
All patients received neoadjuvant chemother-
apy: 97.6% anthracycline and taxane-based che-
motherapy, 0.8% taxane-based (due to cardiac 
comorbidities) and 1.6% other regimens (taxane 
and platinum regimens). One patient underwent 
taxane and platinum regimen due to a concomitant 
primary ovarian cancer and another patient under-
went anthracycline regimen and did not proceed to 
the taxane treatment due to hematologic toxicity 
grade 4 (Tab. 2).
The CEA ratio was ≥ 0.66 in 75.6% and the CA 
15.3 ratio was ≥ 0.8 in and 89.8%.
In 13% of the patients, neoadjuvant radiotherapy 
was performed due to clinically progressive disease 
and/or grade 3/4 adverse events. Of the 16 patients 
that underwent NART, none achieved pCR. In fact, 
only 5 patients experienced downstaging of the 
disease with neoadjuvant treatment at pathologic 
analysis of the specimen. Of the 16 patients, 6 had 
pathologic node positive disease and 3 had ≥ pT3 
disease. 
The totality of patients underwent breast sur-
gery: radical mastectomy in 95.3% and in 4.7% 
breast conserving surgery. 
Adjuvant radiotherapy was performed in 59.8% 
and 7.9% underwent adjuvant chemotherapy with 
capecitabine. 
Only one patient underwent 8 cycles of adju-
vant chemotherapy with capecitabine. The other 
patients discontinued treatment due to grade 3/4 
adverse events (5 patients had hematologic toxicity, 
1 patient had gastrointestinal toxicity, 3 patients 
had hand-foot syndrome and 1 patient had Ste-
vens-Johnson syndrome). 
The tumor pathologic characteristics are de-
scribed in Table 2. The pCR was 48.8%, with 66.9% 
being submitted to axillary lymph node dissec-
tion. In 21% of patients the pathologic N status 
was ≥ 1. Lymphovascular invasion was detected 
in 15%, lymphatic emboli in 7.1%, deep margin 
table 2. Treatment and pathologic characteristics
Treatment characteristics No. (%)
Neoadjuvant chemotherapy
anthracycline and taxane-based 124 (97.6)
Taxane-based only 1 (0.8)
Other 2 (1.6)
cEA pre-treatment/after surgery ratio
≥ 0.66 96 (75.6)
< 0.66 31 (24.4)
cA 15.3 pre-treatment/after surgery ratio
≥ 0.8 114 (89.8)
< 0.8 13 (10.2)
Neoadjuvant radiotherapy 16 (12.6)
type of breast surgery
radical mastectomy 121 (95.3)
Breast conserving surgery 6 (4.7)
adjuvant radiotherapy 76 (59.8)





> 50% 5 (4)
Unknown 31 (24.4)
Lymph nodes removed in surgery
< 10 13 (15.3)
≥ 10 72 (84.7)
Pathology tumor stage [pt]
< pT3 121 (95.3)
≥ pT3 6 (4.7)




Lymphovascular invasion 19 (15)
Lymphatic emboli 9 (7.1)
Deep margin involvement 5 (3.9)
calcification 2 (1.6)
no — number; pcr — pathologic complete response
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involvement in 3.9% and calcifications in 1.6%. In 
30% pathologic celularity was ≥ 10%.
The safety profile of the different neoadjuvant 
regimens was consistent with the known adverse 
events of each agent, which are represented in Ta-
ble 3. The main toxicities observed were grade 1-2. 
The most common grade 3 or 4 adverse event was 
neutropenia. Discontinuation of neoadjuvant treat-
ment due to grade 3/4 toxicities was observed in 17 
patients, of which 3 discontinued also due to clini-
cally detected progressive disease.
Recurrence, overall survival and disease free sur-
vival
After 29 months of median follow-up (interval 
6–82 months), 105 patients (82.7%) were alive and 
in total 38 patients (29.9%) experienced recurrence. 
Briefly, 14 patients recurred locoregionally with 
ganglionar, cutaneous and/or muscular involve-
ment. After local biopsy, TNBC was histology con-
firmed in all 14 patients. Of these patients, 13 were 
submitted to radical mastectomy, 1 to breast con-
serving surgery and 8 underwent adjuvant radio-
therapy. Of the 6 patients that did not go adjuvant 
radiotherapy, 3 had been submitted to neoadjuvant 
radiotherapy due to toxicity or clinical progression 
during NACT, 1 patient had an initial stage IIB and 
2 patients had achieved pCR.
The most frequent distant sites of recurrence 
were lungs (16 patients), brain (10 patients), bone 
(9 patients) and liver (5 patients). One patient de-
veloped renal and peritoneal histologically con-
firmed breast cancer metastasis. The majority of 
patients had 1 or 2 involved sites. Only 6 patients 
had ≥ 3 involved sites of metastatic disease. Of the 
10 patients that developed brain metastasis, 2 were 
submitted to radiosurgery treatment, 5 whole-brain 
radiotherapy, 1 patient underwent brain surgery 
followed by radiosurgery and after local recurrence 
whole-brain radiotherapy. There were 2 patients 
that did not meet the functional status to treat brain 
metastasis and underwent exclusive symptomatic 
treatment.
After recurrence diagnosis, 24 patients under-
went palliative chemotherapy treatment. The re-
maining patients underwent local treatments 
and/or exclusive symptomatic and supportive care 
after recurrence diagnosis. The totality of patients 
treated with palliative chemotherapy did not un-
dergo more than 3 lines of therapy.
The 2-year DFS and OS was 73% (95% CI: 
21.3–22.7) and 89% (95% CI: 23–23.7), respectively. 
In univariate analysis for DFS, neoadjuvant ra-
diotherapy (NART), pCR, BRCA mutation, patho-
logic node and T status and pathologic cellularity 
had significance. In multivariate analysis, being 
submitted to NART [HR: 2.8 (95% CI: 1.2–6.4), 
p = 0.017) and not achieving pCR [HR: 0.3 (95% 
CI: 0.1–1.7), p = 0.011] were associated with higher 
risk of recurrence (Tab. 4). In univariate analysis 
for OS, NART, pCR and pathologic lymphatic em-
boli had significance. In multivariate analysis, being 
submitted to NART [HR = 7.1 (95% CI: 2.3–22.2), 
p = 0.001] and the presence of pathologic lymphatic 
emboli [HR: 4.7 (95% CI: 1.2–17.3), p = 0.022] 
negatively impacted OS (Tab. 4).
The presence of at least one of these variables 
(not achieving pCR and being submitted to NART) 







anemia 62 (48.8%) 7 (5.5%)
Neutropenia 17 (13.4%) 13 (10.2%)
Gastrointestinal
Nausea 41 (32.3%) 5 (3.9%)
Mucositis 35 (27.6%) 5 (3.9%)
constipation 12 (9.4%) 0
Dysgeusia 6 (4.7%) 0
Diarrhea 5 (3.9%) 1 (0.8%)
Vomiting 4 (3.1%) 0
anorexia 2 (1.6%) 1 (0.8%)
hepatitis 1 (0.8%) 1 (0.8%)
Neurotoxicity 25 (19.7%) 2 (1.6%)
cutaneous
alopecia 127 (100%) Na
Onycholysis 12 (9.4%) 3 (2.4%)
hand-foot syndrome 5 (3.9%) 1 (0.8%)
rash 4 (3.1%) 2 (1.6%)
Fatigue 16 (12.6%) 1 (0.8%)
Myalgias 11 (8.7%) 0
Ocular
Watering eyes 3 (2.4%) 0
Dry eye 2 (1.6%) 0
pyrexia 1 (0.8%) 0
hypersensitivity reaction 1 (0.8%) 2 (1.6%)
No. — number; Na — not applicable
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defined a subgroup of patients with a worse DFS at 
24 months than those without these features (59% 
vs. 90%, p < 0.001, respectively). With this data, 
we developed a risk model that is represented in 
Figure 1.
Discussion
Despite the widespread acknowledgment of the 
poor clinical outcome of TNBC, the prognostic val-
ue of specific morphological and biological features 
of these tumors continues to raise a substantial de-
gree of uncertainty and controversy. 
This study represents a real-life cohort, where 
the majority of our TNBC patients had relatively 
large tumors (57.4% with clinical T ≥ 3) and 59.8% 
had positive axillary lymph nodes at presentation. 
The predominant subtype was invasive ductal car-
cinoma and 44.9% had poorly differentiated histol-
ogy. In this study, the prognostic significance of 
putative well-established prognostic factors, such 
as age, menopausal status, clinical and pathologic 
nodal status, size of the tumor, grade, Ki-67, the 
presence of lymphovascular invasion, was assessed. 
Pathologic node and T status and pathologic cel-
lularity were found as prognostic markers in the 
DFS univariate analysis but lost independency in 
multivariate analysis. In multivariate analysis, only 
NART and the non-achievement of pCR impacted 
as independent prognostic factors for disease recur-
rence, identifying a subgroup of higher risk patients 
for early recurrence. Concerning OS, NART and 
the non-achievement of pCR were found as prog-
nostic markers in the univariate analysis, although 
pCR lost its independency in multivariate analysis.
Among patients treated with neoadjuvant che-
motherapy, achievement of a pCR is prognosti-
cally significant. The association between pCR and 
long-term outcome is stronger in patients with ag-
gressive breast cancer subtypes, including TNBC 
[14]. Considering pCR, our results are in line with 
literature, since its non-achievement correlates with 
worst DFS. The role of pCR on patient outcomes 
has been demonstrated to be the highest in TNBC 
and HER2 positive breast cancer [17–19]. In 2014, 
the results of the Collaborative Trials in Neoad-
juvant Breast Cancer (CTNeoBC) pooled analysis 
were published [14]. This study, funded by the Unit-
ed States Food and Drug Administration (FDA), 
included 12 clinical trials and 11,955 patients. The 
authors reported that patients who attained pCR 












≥ 1 risk factor
General population
Months
6                        10                      14                       18                       22                       26
no (%) DFS 24 months p value
General population 127 (100%) 73%
No risk factor 61 (48%) 90%
< 0.001
Not achieving pcr and/or being submitted to NarT 66 (52%) 59%
Figure 1. risk model for disease free survival at 24 months and Kaplan-Meier curve according to risk factors identified 
in the multivariate cox regression
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outcomes and that it was the greatest in aggressive 
tumor subtypes (in patients with TNBC, event free 
survival HR: 0.24, 95% CI: 0.18–0.33, and overall 
survival HR: 0.16, 95% CI: 0.11–0.25). Following 
this report, pCR has been used by the FDA as an 
endpoint to facilitate accelerated approval for cer-
tain agents. In our study, the non-achievement of 
pCR was identified as an independent prognostic 
factor for DFS; however, it did not impact OS per-
haps due to the relatively small cohort and short 
follow-up. Even though the pCR was 48%, in our 
study, there was a significant percentage (66.9%) of 
patients that were submitted to axillary lymph node 
dissection. For women who received neoadjuvant 
therapy, the approach to the axilla usually depends 
on the presence of suspicious nodes prior to neo-
adjuvant therapy and response to treatment. In our 
study there was a significant percentage of patients 
with large tumors and a node positive status. Per 
protocol, in our institution, patients with a node 
positive status undergo axillary lymph node dis-
section. Additionally, some patients with positive 
sentinel lymph node on surgery were also submit-
ted to axillary lymph node dissection, justifying the 
significant percentage of lymph node dissection. 
Nevertheless, considering the comorbidities associ-
ated with axillary lymph node dissection, risk ben-
efit of the procedure should be considered specially 
in patients with clinical N1 disease and a good 
response to neoadjuvant treatment.   
In our study, NART was performed with the ob-
jective of downsizing inoperable tumors in patients 
who had progressive disease and/or grade 3/4 toxic-
ities during neoadjuvant chemotherapy treatment. 
Radiotherapy has been clearly demonstrated to re-
duce locoregional and distant relapse after breast 
conserving surgery and radical mastectomy al-
though its role as a neoadjuvant therapy is not well 
established in terms of outcomes. Neoadjuvant ra-
diotherapy is indicated after chemotherapy if tumor 
resectability is not achieved. There are some studies 
that demonstrate its benefit as neoadjuvant treat-
ment. A study of 134 patients with locally advanced 
breast cancer submitted to neoadjuvant radiother-
apy (with no systemic treatment administered as 
neoadjuvant treatment) demonstrated a pCR in 
15% of the patients, a relapse rate of 61.9%, and 
a 5-year disease free survival and overall survival 
of 39.2% and 55.1%, respectively [20]. In this study 
the hormone receptor status did not influence the 
clinical response to neoadjuvant radiotherapy al-
though non-significantly higher response rate was 
noticed in patients with hormone receptor nega-
tive compared to hormone receptor positive breast 
cancer [20]. However, there are few data about pa-
tients who are initially refractory to neoadjuvant 
chemotherapy and who are submitted to salvage 
radiotherapy. Coelho et al., conducted one of the 
largest retrospective studies of the implementa-
tion of NART in patients refractory to neoadjuvant 
chemotherapy and ineligible for surgical resection. 
The study demonstrated that radiotherapy could be 
an alternative to patients with unresectable tumors 
after neoadjuvant chemotherapy with overall sur-
vival advantage for patients with tumors resected 
after neoadjuvant salvage radiotherapy compared 
with those who were unresected. However, almost 
half of the patients were hormone receptor negative 
and this subset of patients had lower responses to 
neoadjuvant radiotherapy compared with hormone 
receptor positive patients [21].
According to literature, failure in response to sys-
temic therapy is associated with a worse prognosis 
in TNBC and our study corroborates this. To our 
knowledge there are no data regarding the role of 
neoadjuvant radiotherapy as an independent prog-
nostic marker for disease recurrence.     
In TNBC, the association between tumor size 
and nodal status is not as linear as in other breast 
cancer subtypes [15, 22]. Since the pathologic nodal 
status is well established as one of the strongest 
prognostic factors in breast cancer, it was expected 
to show its prognostic value in our study. However, 
some studies did not confirm the prognostic signifi-
cance of the nodal status in TNBC [22, 23].
In TNBC, it has been reported that there is 
a strong correlation with BRCA mutations. Accord-
ing to the literature, approximately two out of nine 
women with TNBC harbor BRCA1 mutation [24]. 
However, several studies have investigated prog-
nosis among BRCA mutation carriers and non-
carriers and the prognostic impact on outcomes 
has not been definitely determined [16, 24]. In our 
study, there is a low number of patients with BRCA 
mutation which can explain the lack of impact on 
prognosis. BRCA mutation testing is performed 
in patients ≤ 60 years old with TNBC, which ex-
plains the significant number of patients with an 
unknown BRCA mutation status.
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One of the main goals of neoadjuvant chemo-
therapy, by allowing the downstaging of the tu-
mor, is to convert candidates for mastectomy to 
breast-conserving surgery. In our study the per-
centage of mastectomy was far superior relative to 
breast conserving surgery, possibly related to the 
elevated percentage of advanced disease at pre-
sentation, the uncertainty about patterns of tumor 
shrinkage and temptation to excise the original 
tumor footprint and patient preference or con-
traindication for adjuvant radiotherapy, as well. 
Nevertheless, with the improvement of neoad-
juvant chemotherapy with increasingly effective 
regimens, we hope to witness an increase in breast 
conserving surgery in TNBC.
This study has some limitations such as the retro-
spective methodology and missing data in patient’s 
records. Nonetheless, the pCR rate in our study 
was higher (48.8%) when compared to the data 
reported in literature (the CTNeoBC pooled analy-
sis reported a pCR rate of 33.6 percent in triple 
negative breast cancer [14]). The study was also 
conducted in a relatively small number of patients 
(127) with a relatively short follow-up time of 29 
months. Nonetheless, it is a real-life cohort from 
a resource-limited hospital.
conclusion
In conclusion, TNBC represents a heteroge-
neous disease with different biological and clinical 
behavior. In this retrospective analysis of real-life 
non-metastatic TNBC, we were able to confirm 
the aggressiveness of this disease and identify 
a high-risk subgroup of patients for early disease 
recurrence. Although there are well-established 
prognostic factors with impact on DFS, in our 
study NART (performed due to refractory tumor 
response to neoadjuvant chemotherapy or signifi-
cant toxicity) and pCR impacted as independent 
prognostic factors for relapse. Given the limited op-
tions after insufficient response to systemic therapy, 
radiotherapy could be a resource for downsizing, 
however, in our cohort it negatively impacted DFS. 
Despite being a highly heterogeneous disease, pCR 
is a well-established prognostic factor in TNBC and 
our study confirmed these results.  
These results reinforce that this high-risk sub-
group of patients might merit a closer follow-up. 
New biomarkers are mandatory for a better strati-
fication of this heterogeneous population and there 
persists a medical need for more efficacious sys-
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